ZFP64

ZFP64 is a C2H2 zinc finger transcription factor that controls cell-fate and differentiation programs by directly binding target gene promoters and, in selected contexts, recruiting co-regulators (PMID:18430783, PMID:35219791). It first emerged as a Notch1 coactivator that associates with the Notch1 intracellular domain, is recruited to the Hes1 and Hey1 promoters, and—itself transactivated by Runx2—suppresses myogenic and promotes osteoblastic differentiation in mesenchymal cells (PMID:18430783). Beyond direct transcriptional activation, ZFP64 can also repress transcription by recruiting HDAC1 to deacetylate and silence the NUMB promoter (PMID:37760477). Its activity is gated post-translationally: PKCα directly phosphorylates ZFP64 at serine 226 to drive nuclear translocation and subsequent transcriptional activation of CSF1 (PMID:35219791). Across multiple tumor settings ZFP64 activates a broad repertoire of direct targets—GAL-1 (PMID:34996504), glycolytic genes including ALDOC, ENO2 and HK2 (PMID:39294751), the antioxidant/ferroptosis genes GCH1 and FTH1 (PMID:40022222), TUBB3 (PMID:39706253), CENPL (PMID:39628712), and the immune checkpoint genes PD-1 and CTLA-4 (PMID:35843097)—thereby supporting glycolysis, stemness, immunosuppression and therapy resistance. ZFP64 expression is itself epigenetically regulated, being activated by KDM1A-dependent removal of H3K9me2 (PMID:39628712) and by CAF-derived lactate driving H3K18 histone lactylation at its locus (PMID:40022222), and its target output can be modulated by the lncRNA FIRRE binding ZFP64 to enhance TUBB3 induction (PMID:39706253). In the nervous system, ZFP64 in Purkinje cells promotes activity-dependent climbing-fiber synapse elimination downstream of P/Q-type voltage-dependent Ca2+ channels by regulating Sema3A expression (PMID:40546958).

1. 2008 High

   Established ZFP64's first mechanistic identity—as a Notch1 coactivator and Runx2 effector—linking it to a differentiation decision between myogenic and osteoblastic fates.

   Evidence Co-IP of ZFP64 with Notch1 ICD, ChIP at Hes1/Hey1 promoters, promoter transactivation, and C2C12 gain/loss-of-function differentiation assays

   PMID:18430783

   Open questions at the time

   • Whether the same Notch-coactivator mechanism operates in the later tumor contexts is untested
   • Direct DNA-binding sequence specificity of ZFP64 not defined
2. 2022 High

   Identified the post-translational switch governing ZFP64 nuclear entry, showing PKCα phosphorylation at S226 converts cytoplasmic ZFP64 into a nuclear CSF1-activating transcription factor that reshapes the tumor immune microenvironment.

   Evidence MS phosphosite mapping, in vitro kinase assay, nuclear fractionation/IF, ChIP-seq at CSF1 promoter, and orthotopic/transgenic HCC mouse models

   PMID:35219791

   Open questions at the time

   • Upstream signals activating PKCα toward ZFP64 not defined
   • Whether S226 phosphorylation regulates targets beyond CSF1 is untested
3. 2022 Medium

   Extended ZFP64 to direct activation of immunosuppression and stemness programs in gastric and esophageal cancers via GAL-1 and the checkpoint genes PD-1/CTLA-4.

   Evidence ChIP-seq and dual-luciferase reporter at GAL-1 promoter (gastric); luciferase reporter and IHC for PD-1/CTLA-4 with orthotopic xenografts (esophageal)

   PMID:34996504 PMID:35843097

   Open questions at the time

   • PD-1/CTLA-4 binding rests on reporter assays without ChIP confirmation
   • Cofactor requirements for these activation events unknown
4. 2023 Medium

   Revealed ZFP64 also functions as a transcriptional repressor by recruiting HDAC1 to deacetylate the NUMB promoter, indirectly amplifying Notch1 signaling.

   Evidence Co-IP of ZFP64–HDAC1, ChIP at NUMB promoter, and knockdown/overexpression in gallbladder cancer models

   PMID:37760477

   Open questions at the time

   • What dictates activator versus repressor mode at a given promoter is unknown
   • Single-lab, limited orthogonal validation of the HDAC1 interaction
5. 2024 Medium

   Defined ZFP64 as a direct driver of glycolytic metabolism and as an epigenetically controlled node, activating glycolysis genes and CENPL while being switched on by KDM1A-mediated H3K9me2 removal.

   Evidence ChIP and dual-luciferase at glycolytic gene promoters with inhibitor rescue (breast); ChIP of KDM1A/H3K9me2 at ZFP64 promoter and rescue (ovarian)

   PMID:39294751 PMID:39628712

   Open questions at the time

   • Direct DNA-binding motif shared across glycolytic targets not defined
   • CENPL regulation supported by a single low-replication study
6. 2025 Medium

   Connected ZFP64 to therapy resistance and lncRNA-modulated transcription, showing CAF-lactate-induced histone lactylation elevates ZFP64 to suppress ferroptosis (GCH1/FTH1), and that FIRRE binds ZFP64 to enhance TUBB3 induction.

   Evidence ChIP/luciferase at GCH1, FTH1 and TUBB3 promoters; H3K18la detection and CAF co-culture; RIP for FIRRE–ZFP64; rescue and xenograft experiments

   PMID:39706253 PMID:40022222

   Open questions at the time

   • Generality of histone-lactylation control of ZFP64 beyond TNBC untested
   • Whether FIRRE alters ZFP64 DNA binding or stability not resolved
7. 2025 Medium

   Placed ZFP64 in neuronal circuit refinement, demonstrating it drives activity-dependent climbing-fiber synapse elimination downstream of P/Q-VDCCs through Sema3A.

   Evidence Purkinje-cell-specific AAV knockdown with electrophysiology, CF morphology, and genetic epistasis with Sema3A and P/Q-VDCC knockdown

   PMID:40546958

   Open questions at the time

   • Direct binding of ZFP64 to the Sema3A locus not shown
   • Single-lab knockdown rather than genetic knockout
8. 2025 Low

   Implicated ZFP64 as a repressor of fetal hemoglobin, showing its knockout de-represses γ-globin in erythroid cell lines.

   Evidence CRISPR-Cas9 knockout in K562 and HUDEP-2 with RT-qPCR for HBG mRNA

   PMID:40392482

   Open questions at the time

   • No promoter binding or mechanistic pathway placement; mRNA readout only
   • Not independently confirmed in primary erythroid cells

• The intrinsic DNA-binding sequence specificity of ZFP64 and the rules determining when it activates versus represses a given promoter remain undefined.
• No consensus binding motif established across its many reported targets
• No structural model of ZFP64 zinc fingers on DNA
• Cofactor composition that distinguishes activator from HDAC1-repressor mode unresolved